Business Standard

Saturday, December 21, 2024 | 11:22 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Bharat Biotech inks pact to commercialise Covid-19 vaccine Covaxin in US

Ocugen, a Nasdaq-listed firm, focuses on developing and commercialising gene therapies to cure blindness diseases

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Premium

Bharat Biotech will supply initial doses to be used in the US upon Ocugen’s receipt of an EUA

Sohini Das
Bharat Biotech’s Covid-19 vaccine Covaxin would soon be available in the US market after the firm announced a tie-up with biopharmaceutical company Ocugen to commercialise it for US.

Ocugen, a Nasdaq-listed firm, focuses on developing and commercialising gene therapies to cure blindness diseases.

It will have the US rights to the vaccine candidate and will be responsible for clinical development, regulatory approval (including EUA) and commercialisation for the US market.

Bharat Biotech will supply initial doses to be used in the US upon Ocugen’s receipt of an EUA.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in